Labcyte Closes $5.3M Series D Financing

Labcyte, Inc., a Sunnyvale, California-based global biotechnology tools company, closed a $5.3m Series D financing.

The round was led by the healthymagination fund, a part of GE Ventures, and also included current investors Abingworth, Alloy Ventures, Cross Atlantic Partners, Delphi Ventures, H&Q Healthcare Investors (NYSE:HQH) and H&Q Life Sciences Investors (NYSE:HQL).

The company intends to use the capitalto to continue to expand its systems.

Led by Mark Fischer-Colbrie, CEO and president, Labcyte develops systems based on the use of acoustic energy to accurately transfer liquids without contact eliminating the use of pipettes.┬áThe company’s instruments are used worldwide throughout the pharmaceutical industry, biotechnology firms, contract research organizations and academic institutions. Customers work across a wide range of scientific research including drug discovery, genomics, proteomics, diagnostics, personalized medicine and imaging mass spectrometry.
Labcyte has 62 global patents, along with additional filings.



Join the discussion